Solasia Pharma K.K.

Tokyo Stock Exchange 4597.T

Solasia Pharma K.K. Cash and Short-Term Investments for the year ending December 31, 2023: USD 5.16 M

Solasia Pharma K.K. Cash and Short-Term Investments is USD 5.16 M for the year ending December 31, 2023, a -15.73% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Solasia Pharma K.K. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 6.12 M, a -1.29% change year over year.
Solasia Pharma K.K. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 6.20 M, a -78.38% change year over year.
Solasia Pharma K.K. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 28.68 M, a -24.25% change year over year.
Solasia Pharma K.K. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 37.87 M, a 2.60% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Tokyo Stock Exchange: 4597.T

Solasia Pharma K.K.

CEO	Mr. Yoshihiro Arai
IPO Date	March 27, 2017
Location	Japan
Headquarters	Sumitomo Fudosan Shiba-Koen Tower
Employees	24
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Clinical Trials Dental Care Drugstores & Retail Pharmacies Non-Alcoholic Beverages

Description

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.

Key trends

Past 5 years